Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

NCT04035473 is registered in ClinicalTrials.gov with Athenex, Inc. as lead sponsor.

NCT NCT04035473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04035473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Lead sponsor
Athenex, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2015
Completion date
March 27, 2019
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor